What’s at stake in the war on marijuana?

According to Brookings Fellow John Hudak, it’s time for the federal government to recognize the serious policy risks born from limiting medical marijuana research. 

 

Of all the controlled substances that the federal government regulates, cannabis is treated in unique ways that impede research. Specifically, the U.S. government has held back the medical community's ability to conduct the type of research that the scientific community considers the experimental gold standard in guiding medical practice. Thus, the use of cannabis for medical treatment is happening in states based largely on anecdotal or limited science. In many cases, patients and doctors operate according to a learn-as-you-go approach—a situation that is inexcusably the fault of federal policies failing to keep pace with changing societal views and state-level legal landscapes.

In “Ending the U.S. government's war on medical marijuana research,” authors John Hudak and Grace Wallack argue that it is time...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.